home / stock / indp / indp quote
Last: | $2.16 |
---|---|
Change Percent: | 2.26% |
Open: | $2.16 |
Close: | $2.16 |
High: | $2.2357 |
Low: | $2.14 |
Volume: | 3,926 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.16 | $2.16 | $2.16 | $2.2357 | $2.14 | 3,926 | 07-02-2024 |
$2.21 | $2.3 | $2.21 | $2.31 | $2.15 | 46,605 | 07-01-2024 |
$2.12 | $2.22 | $2.12 | $2.267 | $2.0602 | 15,021 | 06-28-2024 |
$2.28 | $2.41 | $2.28 | $2.41 | $2.21 | 4,324 | 06-27-2024 |
$2.37 | $2.31 | $2.37 | $2.4214 | $2.31 | 25,289 | 06-26-2024 |
$2.18 | $2.22 | $2.18 | $2.25 | $2.13 | 17,889 | 06-25-2024 |
$2.22 | $2.24 | $2.22 | $2.31 | $2.21 | 7,647 | 06-24-2024 |
$2.25 | $2.32 | $2.25 | $2.33 | $2.175 | 40,998 | 06-21-2024 |
$2.32 | $2.46 | $2.32 | $2.535 | $2.32 | 33,639 | 06-20-2024 |
$2.49 | $2.56 | $2.49 | $2.61 | $2.48 | 24,816 | 06-19-2024 |
$2.49 | $2.56 | $2.49 | $2.61 | $2.48 | 24,816 | 06-18-2024 |
$2.64 | $2.45 | $2.64 | $2.7 | $2.43 | 53,450 | 06-17-2024 |
$2.47 | $2.42 | $2.47 | $2.5 | $2.35 | 16,029 | 06-14-2024 |
$2.44 | $2.39 | $2.44 | $2.46 | $2.34 | 12,998 | 06-13-2024 |
$2.42 | $2.4875 | $2.42 | $2.6299 | $2.32 | 8,739 | 06-12-2024 |
$2.49 | $2.73 | $2.49 | $2.73 | $2.4 | 47,567 | 06-11-2024 |
$2.44 | $2.64 | $2.44 | $2.64 | $2.41 | 20,484 | 06-10-2024 |
$2.65 | $2.69 | $2.65 | $2.7 | $2.55 | 15,705 | 06-07-2024 |
$2.6319 | $2.6 | $2.6319 | $2.755 | $2.56 | 23,230 | 06-06-2024 |
$2.52 | $2.81 | $2.52 | $2.8888 | $2.52 | 37,720 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Indaptus Therapeutics Inc. Company Name:
INDP Stock Symbol:
NASDAQ Market:
Indaptus Therapeutics Inc. Website:
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on ...
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE...